CDY 1.43% 7.1¢ cellmid limited

consumer health thread

  1. 74 Posts.
    lightbulb Created with Sketch. 20
    I thought perhaps a two thread approach would help, given i am expecting a massive rush of new buyer and poster the coming year. One for consumer products, and one for mid-kine research. Well see

    Fillerina market in Australia:

    - Initially i was a bit disappointed with the "Australia only aspect of this distribution, i.e why not "the world", so put it down to a mil or two and forgot about it. A few searches have made me think the Australian market may be bigger than i thought:

    1) $1B spend annually

    https://www.spaandclinic.com.au/aesthetics/australias-spend-cosmetic-treatments-tops-1-billion/

    2) $350m revenue just from 1.5m annual Aus botex injections

    http://www.accs.org.au/images/docs/media/151120-Media-release-Home-based-botox-warning-FINAL.pdf

    3) Fillerina kit $150 a pop

    https://www.ebay.com.au/i/222789876559?chn=ps

    4) Means that 1% of 1.5m treatments a year at $150 a pop +$2.2m additional revenue

    5) We are told part of the value proposition is the people who don't want to do injections, so add 5% to the total market and you get $11m annual revenue just for Australia

    Not bad for a sideline
 
watchlist Created with Sketch. Add CDY (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.